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Strategies aimed at mimicking or enhancing the action of the incretin hormone glucagon-
like peptide 1 (GLP-1) therapeutically improve glucose-stimulated insulin secretion (GSIS);
however, it is not clear whether GLP-1 directly drives insulin secretion in pancreatic islets.
Here, we examined the mechanisms by which GLP-1 stimulates insulin secretion in mouse
and human islets. We found that GLP-1 enhances GSIS at a half-maximal effective
concentration of 0.4 pM. Moreover, we determined that GLP-1 activates PLC, which
increases submembrane diacylglycerol and thereby activates PKC, resulting in membrane
depolarization and increased action potential firing and subsequent stimulation of insulin
secretion. The depolarizing effect of GLP-1 on electrical activity was mimicked by the PKC
activator PMA, occurred without activation of PKA, and persisted in the presence of PKA
inhibitors, the KATP channel blocker tolbutamide, and the L-type Ca2+ channel blocker
isradipine; however, depolarization was abolished by lowering extracellular Na+. The PKC-
dependent effect of GLP-1 on membrane potential and electrical activity was mediated by
activation of Na+-permeable TRPM4 and TRPM5 channels by mobilization of intracellular
Ca2+ from thapsigargin-sensitive Ca2+ stores. Concordantly, GLP-1 effects were negligible
in Trpm4 or Trpm5 KO islets. These data provide important insight into the therapeutic
action of GLP-1 and suggest that circulating levels of this hormone directly stimulate insulin
secretion by b cells.
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Introduction
Type 2 diabetes currently affects approximately 350 million indi-
viduals in the world (1). It is caused by insufficient insulin secre-
tion, often in combination with impaired insulin action (2). The 
reduced insulin secretion has been attributed to impaired β cell 
function, β cell mass, or a combination of the two (2).
Therapies based on the incretin hormone glucagon-like pep-
tide 1 (GLP-1) have been introduced during the last 10 years. They 
include long-lasting GLP-1 analogs and inhibitors of dipeptidyl pep-
tidase 4 (DPP-4), the enzyme degrading the active form of GLP-1 
[GLP-1(7-36) amide] to its less active metabolite [GLP-1(9-36) 
amide]. Their actions culminate in e glucose-dependent stimula-
tion of insulin secretion from the pancreatic β cells (3, 4).
The plasma concentration of biologically active GLP-1 
[GLP-1(7-36) amide] is in the picomolar range and does not increase 
beyond ~20 pM, even after a meal (5, 6). Moreover, administration 
of DPP-4 inhibitors increases the peripheral blood concentration 
of GLP-1 by only a few picomolars and yet results in marked stim-
ulation of insulin secretion and a fall in plasma glucose levels (5, 
6). Effects of physiological levels of GLP-1 in neurons (7), skeletal 
muscle cells (8), hepatocytes (9), and adipocytes (10, 11) have been 
reported. Nevertheless, most in vitro studies of the effects GLP-1 on 
pancreatic islet function use nanomolar (1–100 nM) concentrations 
of GLP-1 (12–15), i.e., levels >100- to 10,000-fold higher than those 
occurring physiologically. The use of such high concentrations is 
predicated on receptor-binding assays and measurements of intra-
cellular cAMP accumulation, which suggest a half-maximal effective 
concentration (EC50) of approximately 5 nM (16–18). Because of the 
huge discrepancy between the plasma GLP-1(7-36) levels and those 
assumed required to stimulate insulin secretion in isolated pancre-
atic islets, it has been proposed that GLP-1 released from the intesti-
nal L cells acts by activation of vago-vagal reflexes that culminate in 
neurally mediated stimulation of insulin secretion (19).
The GLP-1 receptor (GLP-1R) is coupled to the GTP-bind-
ing protein G
αs, which activates adenyl cyclase, and many of the 
effects of GLP-1 are mediated by an increase in the intracellular 
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Results
Picomolar concentrations of GLP-1 stimulate 
insulin secretion, electrical activity, and [Ca2+]i 
oscillations. In mouse islets, GLP-1 potentiated 
glucose-induced insulin secretion in a dose- 
dependent manner at between 0.1 pM and 10 
pM, with a calculated EC50 of approximately 
0.4 pM (Figure 1A). Thus, the stimulatory effect 
of 1 pM GLP-1 was maximal and as strong as 
that observed at 10 nM, which (if anything) 
produced less stimulation than a 1,000- to 
10,000-fold lower concentration.
We determined the glucose dependence 
of the stimulatory effect of 1 pM GLP-1 (Figure 
1B). Whereas GLP-1 was without effect at 1 and 
4 mM glucose, insulin secretion at 6 and 10 
mM was strongly potentiated. Thus, the stimu-
latory effect of picomolar levels of GLP-1 is only 
observed at glucose concentrations that are themselves stimulatory.
We confirmed the stimulatory capacity physiological con-
centrations of GLP-1 using the perfused pancreas preparation, 
whereby GLP-1 is delivered by the vascular system (Figure 1C). 
Increasing glucose from 1 to 6 mM evoked a biphasic stimu-
lation of insulin secretion and transiently increased it from a 
basal rate of 0.1 ng/min to a peak value of approximately 2 ng/
min, after which the secretory rate fell to approximately 0.5 
ng/min. Subsequent administration of 1 pM GLP-1 produced a 
marked biphasic stimulation of insulin secretion, in excess of 
that evoked by 6 mM glucose alone, to a new peak value of 3 
ng/min, before declining to a new plateau of of approximately 
1.5 ng/min.
cAMP levels. However, coupling to the GTP-binding proteins Gαi/o 
and Gαq/11 has also been reported (20–23), but the downstream 
functional consequences remain largely unexplored.
Here, we have determined the concentration dependence 
of the stimulatory effect of GLP-1 on glucose-stimulated insulin 
secretion in intact mouse and human pancreatic islets. We demon-
strate that GLP-1 stimulates insulin secretion with an EC50 of 
approximately 0.4 pM and that a concentration of 1 pM is at least as 
stimulatory as 10 nM. This effect involves activation of the GLP-1R 
and is PKC-dependent and mediated by membrane depolarization 
due to activation of Na+-permeable TRPM4 and TRPM5 channels, 
culminating in increased action potential firing rates and Ca2+- 
dependent stimulation of insulin exocytosis.
Figure 1. Stimulatory effects of picomolar concen-
trations of GLP-1 on insulin secretion, electrical 
activity, and [Ca2+]i. (A) Insulin secretion measured 
at 6 mM glucose (black circle) and increasing con-
centrations of GLP-1 (n = 4–8 experiments). The 
white circle shows insulin secretion measured at 
1 mM glucose in the absence of GLP-1. †P<0.05 vs. 
1 mM glucose, *P < 0.05 vs. 6 mM glucose (1-way 
ANOVA with Dunnett’s post-hoc test). (B) Insulin 
secretion at 1, 4, 6, and 10 mM glucose in the 
absence and presence of 1 pM GLP-1 (n = 9 exper-
iments). *P < 0.01 vs. no GLP-1 (Student’s t test). 
(C) GLP-1 (1 pM) stimulated insulin secretion from 
perfused mouse pancreas (n = 4). (D) Membrane 
potential recording from a β cell exposed sequen-
tially to 1 pM and 10 nM GLP-1 (representative of 
24 of 25 cells). (E) Spontaneous [Ca2+]i oscillations 
in a β cell within an intact islet exposed to 1 pM 
GLP-1 (representative of 23 of 35 cells in 3 islets 
from 3 mice). (F) Insulin secretion in mouse islets 
at 6 mM glucose in the absence and presence of 1 
pM GLP-1 and/or 100 nM exendin (9-39) (Ex9-39). 
*P < 0.05 vs. 1 mM glucose, †P < 0.05 vs. 6 mM 
glucose (n = 3–5; 1-way ANOVA with Dunnett’s 
post-hoc test). (G) As in F but using human islets 
(n = 8–12 with islets from 2–4 donors). *P < 0.05 
vs. 1 mM glucose, †P < <0.05 vs. 6 mM glucose  
(n = 3–5; 1-way ANOVA with Dunnett’s post-hoc test).
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approximately 5% of the cells (similar to the 
fraction of cells generating spontaneous action 
potentials). However, GLP-1 (consistent with 
data of Figure 1D and previous reports, see ref. 
24) resulted in substantial recruitment of cells, 
and in the simultaneous presence of 1 pM GLP-1 
and 6 mM glucose, 65% of cells showed [Ca2+]i 
oscillations. A similar increase in the fraction of cells exhibit-
ing [Ca2+]i oscillations was observed when glucose was elevated 
from 6 to 20 mM (25).
We finally confirmed that the effects of 1 pM GLP-1 on glu-
cose-induced insulin secretion can be blocked by the GLP-1R 
antagonist exendin (9-39). In this series of experiments, GLP-1 
potentiated insulin secretion at 6 mM glucose 2.5-fold, an effect 
that was completely reversed by exendin (9-39) (Figure 1F). In 
addition, picomolar concentrations of GLP-1 stimulated insulin 
secretion in human islets, an effect that was likewise antagonized 
by exendin (9-39) (Figure 1G). These observations suggest that the 
effects of picomolar levels of GLP-1 in both mouse and human β 
cells are mediated by the previously characterized GLP-1R (17).
Picomolar concentrations of GLP-1 stimulate L-type Ca2+ channel 
activity and β cell exocytosis. In single mouse β cells exposed to 6 
mM glucose, addition of 1 pM GLP-1 increased the integrated Ca2+ 
current (QCa) evoked by a 20-ms voltage-clamp pulse from –70 
mV to 0 mV by approximately 15%, from –2.6 ± 0.47 pC to –3.2 ± 
0.59 pC (P < 0.01 by paired Student’s t test; Figure 2A). In previous 
Insulin secretion is secondary to β cell electrical activity. We 
therefore correlated the stimulation of insulin secretion by low 
and high concentrations of GLP-1 to the effects on electrical activ-
ity (Figure 1D). In single β cells exposed to 6 mM glucose alone, 
the membrane potential averaged –66 ± 7 mV (n = 36), but only 
a fraction of these cells (10%, 4 of 40 cells) generated spontane-
ous action potentials, and then only transiently upon addition of 
glucose, echoing the transient stimulation of insulin secretion. 
However, upon application of 1 pM GLP-1, action potential firing 
was initiated in almost every cell (24 of 25 cells). At steady state, 
the rate of action potential firing in β cells exposed to 6 mM glu-
cose averaged 0.003 ± 0.003 Hz, which increased to 3.4 ± 0.3 Hz 
(n = 24) after addition of 1 pM GLP-1. The response to 1 pM GLP-1 
was at least as strong as that evoked by a 10,000-fold higher con-
centration of the incretin hormone (Figure 1D).
The effects of GLP-1 on electrical activity correlated with 
the induction of [Ca2+]i oscillations in a subset of cells within 
intact mouse pancreatic islets (Figure 1E). At 6 mM glucose 
alone, spontaneous [Ca2+]i oscillations were seen in only 
Figure 2. Stimulatory effects of low concentrations of 
GLP-1 depend on L-type Ca2+ channels. (A) GLP-1  
(1 pM) enhances mouse β cell Ca2+ currents (ICa) evoked 
by 20-ms depolarization from –70 mV to 0 mV (n = 7 
cells from 5 mice). (B) Current-voltage (I-V) relation-
ships of whole-cell Ca2+ currents in the absence (black) 
and presence (red) of GLP-1. Current amplitudes have 
been normalized to cell capacitance. Ca2+ current acti-
vation curves are shown in the inset in the absence and 
presence of GLP-1. *P < 0.05 vs. control by paired Stu-
dent’s t test (n = 5 cells from 3 mice). (C) GLP-1 inhibits 
ICa when added in the presence of isradipine (added 5 
minutes prior to the addition of GLP-1) (n = 5 cells from 
3 mice). (D) Effects of GLP-1 on insulin secretion in 
mouse islets in the absence and presence of GLP-1 
and/or isradipine. Isradipine was included during the 
30-minute preincubation. *P < 0.05 vs. 1 mM glucose; 
†P < 0.05 vs. 6 mM glucose; ‡P < 0.01 vs. 6 mM glucose 
plus GLP-1 (n = 7–8; 1-way ANOVA with Dunnett’s post-
hoc test). (E and F) As in A and C but using human β 
cells (n = 13 cells from 6 donors in E; n = 6 cells from 3 
donors in F). Rectangles indicate the period used for 
measuring charge entry (QCa) to avoid contribution of 
voltage-gated Na+ current (initial spiky component). 
(G) Exocytosis measured as an increase in membrane 
capacitance evoked by 500-ms depolarizations from  
–70 mV to 0 mV under control conditions (6 mM 
glucose, black) and 10 minutes after addition of GLP-1 
(red). A control experiment showing that when GLP-1 
was not added, the exocytotic responses remained 
small and stable for 10 minutes (blue; n = 5), is also 
shown. (H) Exocytosis elicited by a train of three 500-
ms depolarizations from –70 mV to 0 mV in a human β 
cell before (black) and 10 minutes after (red) the addi-
tion of GLP-1 (representative of 5 cells from 3 donors).
The Journal of Clinical Investigation   R e s e a R c h  a R t i c l e
4 7 1 7jci.org   Volume 125   Number 12   December 2015
In human β cells, GLP-1 increased the 
L-type Ca2+ current from –3.0 ± 0.6 pC to –3.4 ± 
0.8 pC (P < 0.05, paired Student’s t test; Figure 
2E). Application of isradipine inhibited QCa by 
48% ± 9% (P < 0.05), and GLP-1 had no effect 
in the presence of the blocker (Figure 2F).
Insulin granule exocytosis evoked by 
500-ms depolarizations from –70 mV to 0 mV increased approx-
imately 5-fold in response to application of 1 pM GLP-1, from 7±4 
fF under basal conditions to 36 ± 18 fF 10 minutes after addition 
of the hormone (P < 0.05, paired Student’s t test; Figure 2G). In 
separate control experiments, no spontaneous increase in exo-
cytosis was detected over 10 minutes in the absence of GLP-1 
(Figure 2G, bottom). In addition, GLP-1 (1 pM) enhanced depo-
larization-evoked exocytosis in human β cells; the responses to 
the first depolarization of a train averaged 95 ± 23 fF and 163 ± 
36 fF (P < 0.05, paired Student’s t test; Figure 2H) in the absence 
and presence of 1 pM GLP-1, respectively.
Low concentrations of GLP-1 stimulate insulin secretion by a 
PKA-independent mechanism. We have previously demonstrated 
that high (supraphysiological) concentrations of GLP-1 potentiate 
glucose-induced insulin secretion by a PKA-dependent mechanism 
(26). We confirmed that this is also the case for low (picomolar) GLP-
1 concentrations (Figure 3A). In these experiments, GLP-1 (1 pM) 
enhanced glucose-induced insulin secretion by >175%. Inclusion 
of the membrane-permeable PKA inhibitor myristoylated protein 
kinase inhibitor (myr-PKI; 1 μM) reduced the stimulatory effect of 
GLP-1 by 60%. Importantly, 40% of the stimulatory effect of GLP-1 
was resistant to myr-PKI. Similar effects were observed with PKA, 
which was inhibited with 8-bromoadenosine-3′, 5′-cyclic mono-
phosphorothioate, Rp-isomer (Rp-8-Br-cAMPS) (data not shown). 
experiments using 10 nM GLP-1, no effect on QCa was detected 
(26), a finding we confirmed (data not shown).
Figure 2B shows the peak Ca2+ current-voltage relationships 
recorded under control conditions and in the presence of 1 pM GLP-1. 
GLP-1 increased the peak Ca2+ currents during pulses to mem-
brane potentials of between –20 mV and +20 mV by 10% to 15%. 
We examined whether the increased peak Ca2+ current amplitude 
was associated with a shift in the voltage dependence of the gating. 
However, no differences in the activation parameters were observed 
between control conditions, which, following addition of GLP-1 and 
Vh (the membrane potential at which activation is half-maximal; see 
Methods and Equation 1), averaged –17 ± 1 mV and –17 ± 2 mV in the 
absence and presence of 1 pM GLP-1, respectively.
The increase in QCa produced by 1 pM GLP-1 reflects acti-
vation of L-type Ca2+ channels (Figure 2C). The L-type Ca2+ 
channel blocker isradipine reduced QCa from –2.6 ± 0.70 pC to 
–0.68 ± 0.09 pC (P < 0.01 by paired Student’s t test). When 1 
pM GLP-1 was added in the presence of isradipine, it decreased 
QCa to –0.59 ± 0.09 pC (P < 0.05 vs. isradipine alone; paired Stu-
dent’s t test). The significance of L-type Ca2+ channels was fur-
ther explored by measurements of glucose- and GLP-1–induced 
insulin secretion (Figure 2D). GLP-1 (1 pM) potentiated insulin 
secretion at 6 mM glucose by 200%. This effect was almost 
completely abrogated (–85%) by isradipine.
Figure 3. PKA-independent effects of GLP-1. (A) 
Effects of glucose and 1 pM GLP-1 on insulin secre-
tion in mouse islets in the absence and presence of 
the membrane-permeable PKA inhibitor myr-PKI 
(1 μM; introduced during 30-minute preincuba-
tion). †P < 0.05 vs. 1 mM glucose; *P < 0.01 vs. 6 
mM glucose; ‡P < 0.01 vs. 6 mM glucose plus 1 pM 
GLP-1; §P < 0.01 vs. 6 mM glucose and 1 μM myr-PKI 
(n = 8 experiments; 1-way ANOVA with Dunnett’s 
post-hoc test). (B) As in A but using human islets 
(n = 6–7 from 3 donors, not the same as in Figure 
1G) and using Rp-8-Br-cAMPS to inhibit PKA. (C) 
Changes in [cAMP]i concentration in response 
to increasing concentrations of GLP-1 (indicated 
above the traces) measured using recombinant 
cAMP sensor Epac2-camps in 2 representative 
cells (continuous and dotted lines). The CFP/YFP 
ratio R has been normalized to its initial value R0. 
(D) Relationship between GLP-1 concentration and 
elevation of [cAMP]i (n = 33 cells from 4 mice). 
The dose-response curve was fit to a Hill equation 
(Equation 2). (E) PKA activity measured in single 
cells from PKI-pretreated (n = 22, white squares) 
and control (n = 24, black squares) cells. GLP-1, 
3-isobutyl-1-methylxanthine (IBMX) and forskolin 
were added as indicated. (F) Basal YFP/CFP ratio 
in control (n = 67) and PKI-pretreated (n = 65, 1 
hour, 10 μM) islet cells. *P < 0.05 (Mann-Whitney 
nonpaired test).
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Picomolar concentrations of GLP-1 activate 
PKC. It has been reported that GLP-1, in addition 
to activating PKA, activates PKC (29). Direct mea-
surement of PKC activity using in vitro substrates 
requires large quantities of cells and is not feasible 
for studies on pancreatic islet cells. However, once 
activated, PKC phosphorylates numerous endoge-
nous substrates, some of which may be used as 
a downstream readout of its activity. PKC is known to phospho-
rylate and activate protein kinase D1 (PKD1) (30). We assessed 
the levels of activated endogenous PKD1 under basal conditions 
and in the presence of 1 pM or 1 nM GLP-1 with Western blotting, 
using antibodies specific for phosphorylated PKD1. Acetylcholine 
(ACh; 20 μM), an agonist known to cause PKC activation in β cells 
(31), was used as a positive control. As shown in Figure 4, A and 
B, stimulation of islets with 1 pM or 1 nM GLP-1 increased PKD1 
phosphorylation by an average of 200%. GLP-1 had virtually iden-
tical effects in the absence and presence of the ATP-regulated K+ 
(KATP) channel activator diazoxide (100 μM), indicating that the 
activation of PKC by GLP-1 is not secondary to the stimulation 
of electrical activity (data not shown). In parallel measurements, 
ACh increased PKD1 phosphorylation by >1,000%. The effects of 
both GLP-1 and ACh were reversed by bisindolylmaleimide (BIM), 
consistent with the idea that activation of PKD1 is mediated by 
activation of PKC.
We also measured the effect of GLP-1 on the submembrane lev-
els of diacylglycerol ([DAG]i) in pancreatic islet cells using a genet-
ically encoded probe, Upward DAG (32). Addition of GLP-1 at con-
centrations as low as 1 pM resulted in a rapid and reversible increase 
in [DAG]i levels (Figure 4C). Notably, application of a 10,000-fold 
higher concentration of GLP-1 did not result in a further increase 
in [DAG]i (Figure 4, C and D). In fact, the response to the high con-
centration of GLP-1 was, if anything, lower than that produced by 1 
Like GLP-1, the adenylate cyclase activator forskolin potentiated 
glucose-induced insulin secretion. This effect was also reversed by 
myr-PKI, but the suppression was stronger than that for glucose and 
no myr-PKI–resistant component of secretion was observed. We 
conclude that the stimulatory effects of GLP-1 on insulin secretion 
are mediated by mechanisms that are partially PKA independent.
An indication of a PKA-independent effect was observed in 
human islets when PKA was inhibited by Rp-8-Br-cAMPS (Figure 
3B), but this effect did not attain statistical significance.
We measured the effect of increasing concentrations of GLP-1 
on cytoplasmic cAMP levels ([cAMP]i) in pancreatic islet cells 
using the genetically encoded Förster resonance energy trans-
fer (FRET) reporter Epac2-camps (27). GLP-1 at concentrations 
below 1 nM had no effect on [cAMP]i, whereas higher concentra-
tions (≥1 nM) consistently increased [cAMP]i (Figure 3C), with an 
EC50 of 5.7 ± 0.9 nM (Figure 3D).
We monitored PKA activity using an AKAR3 FRET sensor 
(28). In agreement with the cAMP measurements, addition of 
GLP-1 (1 pM) did not result in any activation of PKA, regardless of 
whether the experiments were conducted in the absence or pres-
ence of myr-PKI, but the response to the combination of forskolin 
and 3-isobutyl-1-methylxanthine was reduced by approximately 
70% in the presence of myr-PKI (Figure 3E). Basal PKA activ-
ity (measured as the initial YFP/CFP ratio) was reduced in cells 
treated with myr-PKI (Figure 3F).
Figure 4. PKC-dependent effects of GLP-1. (A) Rep-
resentative blots of activated PKD1 and total PKD1 
in mouse islets. p-PKD, phosphorylated PKD1. (B) 
Mean fold change in activated PKD1 relative to no 
stimulation control in response to GLP-1 in untreated 
or BIM-treated islets. The number of independent 
experiments (n) is indicated above the each bar. Mean 
± SEM (where n > 2) or mean ± range (n = 2). *P = 0.01 
vs. unstimulated; †P < 0.05 vs. 1 nM GLP-1 alone; ‡P 
< 0.05 vs. ACh alone (1-way ANOVA with Dunnett’s 
post-hoc test). (C) The effect of GLP-1 on [DAG]i mea-
sured in single cells from dispersed pancreatic islets. 
Characteristic responses to 1 pM and 10 nM GLP-1 as 
well as 1 μM ACh (added as indicated above the trace, 
n = 9). (D) Comparison of the effect of 1 and 10 pM 
GLP-1 on [DAG]i (n = 30 cells from 2 mice). All values 
are statistically higher than baseline (P < 0.05), apart 
from 10 nM GLP-1. *P < 0.05 vs. 1 pM GLP-1; †P < 0.05 
vs. baseline (Friedman ANOVA with Dunn-Bonferroni 
post-hoc test). (E and F) Effects of 1 pM GLP-1 on 
insulin secretion in the absence and presence of the 
membrane-permeable PKC inhibitors (BIM, n = 9; calp-
hostin C, n = 4) (100 nM; introduced during 30-minute 
preincubation). *P < 0.05 vs. 1 mM glucose, †P < 0.05 
vs. 6 mM glucose, ‡P < 0.05 vs. 6 mM glucose plus 1 pM 
GLP-1 (1-way ANOVA with Dunnett’s post-hoc test).
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pM. ACh, when used at the low concentration of 1 μM, also evoked 
a small increase in [DAG]i. We conclude that 1 pM GLP-1 is a fairly 
strong activator of PLC, with a resultant increase in [DAG]i.
We confirmed the involvement of PKC in the stimulatory 
effect of GLP-1 on insulin secretion using the PKC inhibitors BIM 
and calphostin C (Figure 4, E and F). Both compounds abolished 
the stimulatory effect of GLP-1.
Human GLP-1R functionally activates a G
αq chimera. It is well 
established that the GLP-1R activates G
αs and thereby increases 
cAMP production. However, it has been suggested that GLP-1 can 
also bind to G
αi and Gαq (20–23), which are linked to activation of 
PLC, generation of DAG, and activation of PKC. We coexpressed 
the GLP-1R with mammalian G
αs and Gαq as previously described 
(33). Stimulation of the GLP-1R expressed in the G
αq-containing 
yeast strain resulted in a robust response (Figure 5).
cAMP/PKA-independent and PLC/PKC-dependent effects 
of GLP-1. We tested the effects of low concentrations of GLP-1 
on electrical activity in the presence of the PKA inhibitors 
Rp-8-Br-cAMPS and myr-PKI (Figure 6A). Unexpectedly, and 
unlike what has been previously reported for high concentrations 
of the hormone (26), 1 pM GLP-1 remained capable of initiating 
electrical activity under these experimental conditions. This 
effect appeared qualitatively similar to that observed under con-
trol conditions (cf. Figure 1D).
The stimulatory effect of low concentrations of GLP-1 was 
mimicked by the PKC activator PMA (Figure 6B). Like GLP-1, 
PMA depolarized the β cell and initiated action potential firing. 
In the presence of PMA, GLP-1 exerted no additive stimulatory 
effect (data not shown). Application of U73122, an inhibitor of 
PLC, reversibly antagonized the stimulatory effect of GLP-1 on 
β cell electrical activity (Figure 6C), in agreement with a previ-
ous report (29).
Collectively, the data in Figures 3 to 6 suggest that GLP-1 
depolarizes the β cell and triggers action potential firing by a 
PKA-independent but PKC-dependent mechanism that involves 
activation of PLC by G
αq-coupled GLP-1Rs.
KATP channel–dependent and –independent effects of GLP-1. It 
has previously been reported that high concentrations of GLP-1 
stimulate electrical activity and insulin secretion by inhibition 
of KATP channels (12–15). Application of 1 pM GLP-1 was with-
out detectable inhibitory effect on whole-cell membrane con-
ductance in the presence of 6 mM glucose (Figure 7, A and B). 
We confirmed that KATP channel activity, albeit at a low level, 
persisted in the presence of 6 mM glucose (Figure 7, C and D). 
Figure 5. Activation of Gαq by GLP-1. Dose-response curves of GLP-1 in 
yeast strains expressing GPA1/Gαq and GPA1/Gαs chimaeras. Activation 
of the reporter gene was calculated as a percentage of the maximum 
response observed (n = 7–8 experiments).
Figure 6. PKA-independent stimulation of β cell elec-
trical activity. (A) Representative membrane potential 
recording from a single β cell pretreated with 100 μM 
Rp-8-Br-cAMPS (n = 4 cells from 2 mice) or myr-PKI 
(n = 4 cells from 2 mice, not shown). Note initiation of 
electrical activity by GLP-1 in the presence of  
Rp-8-Br-cAMPS. (B) Effect of the PKC activator PMA on 
membrane potential (n = 5 cells from 4 mice). (C) Effect 
of the PLC inhibitor U73122 on action potential firing 
triggered by 1 pM GLP-1 (n = 8 cells from 6 mice). Note 
reversible inhibition. All measurements were performed 
using the perforated patch whole-cell technique in the 
presence of 6 mM glucose.
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Thus, addition of the KATP channel blocker tolbutamide reduced 
membrane conductance by 50%. Interestingly, addition of GLP-1 
(1 pM) in the continued presence of tolbutamide increased the 
whole-cell membrane conductance.
We characterized this KATP channel–independent conductance 
by whole-cell voltage-clamp measurements. In 6 β cells, application 
of GLP-1 evoked an inward current when holding at –70 mV that 
averaged –9 ± 2 pA (P < 0.001, paired Student’s t test; Figure 7E). 
Reduction of extracellular Na+ in the presence of GLP-1 abolished 
this current and reduced the holding current by 13 ± 4 pA (P < 0.01, 
paired Student’s t test). When extracellular Na+ was reduced in the 
presence of 6 mM glucose alone (i.e., without GLP-1), the reduction 
of the holding current was much smaller and amounted to only 3 ± 
1 pA (Figure 7, F and G). Thus, we conclude that GLP-1 depolarizes 
the β cell by activation of Na+-permeable conductance that is acti-
vated to a much lower extent by glucose alone. The latter conclusion 
is in agreement with the reported weak effects of Na+ removal on 
glucose-induced electrical activity (34).
KATP channel–independent effect is mediated by activation of 
TRPM4 and TRPM5 channels. We used pharmacological ion chan-
nel blockers to establish the electrophysiological basis underlying 
the stimulatory effects of low concentrations of GLP-1 on β cell 
electrical activity. We first ascertained that GLP-1 remains capa-
ble of stimulating β cell electrical activity, even when KATP channel 
activity has been pharmacologically suppressed. Figure 8 shows 
membrane potential recordings from mouse and human β cells 
exposed to 6 mM glucose. Whereas mouse β cells are electrically 
silent at this glucose concentration, human β cells are electrically 
active and fire spontaneous action potentials at a high frequency. 
In both mouse and human β cells, addition of the KATP channel 
blocker tolbutamide resulted in membrane depolarization and 
stimulation of action potential firing. The cells were then hyper-
polarized, and action potential firing was reduced by injection of 
negative current. In the hyperpolarized mouse β cells exposed to 
tolbutamide, addition of GLP-1 still resulted in a 60-fold increase 
in action potential firing, from 0.06 ± 0.03 Hz in the presence of 
glucose and tolbutamide alone to 3.6 ± 0.6 Hz in the presence of 
GLP-1 (P < 0.005, paired Student’s t test). In similarly hyperpolar-
ized human β cells, 1 pM GLP-1 increased action potential firing 
in the presence of tolbutamide >25-fold (Figure 8B), from a basal 
rate of 0.04 ± 0.02 Hz to 1.1 ± 0.74 Hz (P < 0.001, paired Student’s 
t test). These experiments suggest that GLP-1 depolarizes mouse 
and human β cells by a mechanism that is (at least partially) KATP 
channel independent.
In addition, we tested the effects of GLP-1 on electrical 
activity in mouse β cells in the presence of the L-type Ca2+ chan-
nel blocker isradipine. As shown in Figure 8C, isradipine inhib-
ited action potential firing. GLP-1 application in the presence 
Figure 7. Physiological concentrations of GLP-1 acti-
vate a depolarizing membrane current in β cells. (A) 
Whole-cell resting currents activated by application 
of ±10 mV voltage pulses from a holding potential of 
–70 mV. Measurements were made at 6 mM glucose 
alone (black trace) and 10 minutes after addition of 1 
pM GLP-1 (red trace). (B) Summary of effects of 1 pM 
GLP-1 on resting membrane conductance (G) calcu-
lated from the experiments in A. Note that GLP-1  
is without a detectable inhibitory effect (n = 4 cells 
from 4 mice). (C) As in A but testing responses at 6 
mM glucose alone (black trace) after addition of 100 
μM tolbutamide (gray trace) and following addition 
of GLP-1 in the continued presence of glucose and 
tolbutamide (red trace). (D) Summary of effects 
of tolbutamide and GLP-1 on membrane conduc-
tance (G) calculated from the current excursions in 
response to voltage pulses (C) and expressed as a 
percentage of that at 6 mM glucose. *P < 0.05 vs. 6 
mM glucose; †P < 0.05 vs. 6 glucose plus tolbutamide 
(n = 5 from 4 mice; 1-way ANOVA with Dunnett’s 
post-hoc test). (E) Membrane current at –70 mV 
recorded in the presence of 6 mM glucose before and 
after addition of 1 pM GLP-1 and effect of lowering 
[Na+]o from 140 mM to 28 mM (“20% Na
+”). (F) As in 
E but showing effects of lowering [Na+]o in the pres-
ence of 6 mM glucose alone. (G) Histogram summa-
rizing effects of lowering [Na+]o on the current at –70 
mV (ΔI) in the presence of 6 mM glucose alone (n = 8 
cells from 4 mice) or in the presence of 6 mM glucose 
and 1 pM GLP-1 (n = 6 cells from 4 mice). *P < 0.01 vs. 
normal [Na+]o (Student’s t test) All measurements 
in this figure were performed using the perforated 
patch whole-cell technique.
The Journal of Clinical Investigation   R e s e a R c h  a R t i c l e
4 7 2 1jci.org   Volume 125   Number 12   December 2015
This observation is in good agreement with the 
finding that only 5% of the β cells are electrically 
active and generate Ca2+ oscillations at 6 mM 
glucose (Figure 1E). We conclude, in agreement 
with earlier reports (25, 36), that increasing glu-
cose concentrations stimulate insulin secretion 
by recruitment of β cells.
We explored the functional significance 
of TRPM4 and TRPM5 channels further by membrane potential 
recordings. Trpm4–/– β cells retained some limited responsiveness 
to GLP-1 (Figure 9E), but the effect was weak compared with that in 
wild-type cells (Figure 9D). β Cells in Trpm5–/– islets were completely 
refractory to stimulation with GLP-1 (Figure 9F). The effects of 
GLP-1 on action potential firing in wild-type, Trpm4–/–, and Trpm5–/– 
β cells are summarized in Figure 9G. The strong suppression of 
insulin secretion evoked by GLP-1 in Trpm4–/– and Trpm5–/– islets 
is echoed by equally strong reductions in action potential firing.
GLP-1 increases [Ca2+]i in hyperpolarized β cells. How does 
GLP-1 activate the TRPM4 and TRPM5 channels? It has been 
reported that GLP-1 increases the islet content of NAADP 
(37), which may release Ca2+ from intracellular acidic stores 
by activation of two-pore channel 1 (TPC1) or TPC2 (38). This 
would provide a potential link between GLP-1 and activation of 
TRPM4 and TRPM5 channels, which are Ca2+ activated (37). We 
investigated this using Tpc1 Tpc2 double KO (DKO) mice. How-
ever, Tpc1 Tpc2 DKO islets retained full responsiveness to GLP-1 
with regard to both secretion (Figure 10, A and B) and electrical 
activity (Figure 10C). Tpc1 Tpc2 DKO islets were also responsive 
to 20 mM glucose (Supplemental Figure 3, A and B)
Activation of PLC by GLP-1 (see above) could be expected 
to increase [Ca2+]i by InsP3-dependent mobilization from intra-
cellular stores. To address this possibility, we measured [Ca2+]i in 
isolated β cells. In agreement with the [Ca2+]i measurements in 
intact pancreatic islets (Figure 1E), application of 1 pM GLP-1 in 
the presence of 6 mM glucose consistently induced rapid [Ca2+]i 
oscillations (Figure 10D). We then repeated the experiment in the 
presence of the KATP channel activator diazoxide (200 μM). Appli-
cation of diazoxide reduced basal [Ca2+]i at 6 mM glucose. Interest-
of isradipine remained capable of depolarizing the β cell but 
was without stimulatory effect on action potential firing, con-
sistent with the important role played by L-type Ca2+ channels 
in β cell electrical activity (35) and secretion (Figure 2D). In the 
absence of regenerative electrical activity, the effect of GLP-1 
on the β cell membrane potential could be accurately measured. 
Under these conditions, 1 pM GLP-1 depolarized the β cells by 
11 ± 2 mV (P < 0.01, paired Student’s t test), an effect that was 
fully reversed upon lowering of extracellular Na+ concentration 
([Na+]o) (20% of normal [Na+]o). Thus, the depolarizing effect of 
GLP-1 was not mediated by activation of L-type Ca2+ channels 
but rather a conductance permeable to Na+ (cf. Figure 7E).
Role of TRPM4 and TRPM5 channels in electrical activity and 
insulin secretion evoked by GLP-1. Preliminary experiments sug-
gested that the stimulatory effects of GLP-1 on electrical activity 
and insulin secretion were sensitive to 9-phenanthrol, an inhibitor 
of Ca2+-activated TRPM4 Na+-permeable ion channels (ref. 23 and 
Supplemental Figure 1, A and B; supplemental material available 
online with this article; doi:10.1172/JCI81975DS1). We explored 
this possibility further by comparing the effects of GLP-1 on insulin 
secretion in islets from wild-type and Trpm4–/– mice. We also tested 
the effects of ablating TRPM5 channels, which are expressed in 
pancreatic β cells and similarly regulated (23).
In wild-type islets, the stimulatory effect of 6 mM glucose was 
potentiated by approximately 85% in the presence of 10 pM GLP-1 
(Figure 9A), an effect that did not occur in Trpm4–/– islets (Figure 
9B) or Trpm5–/– islets (Figure 9C). By contrast, Trpm4–/– and Trpm5–/– 
islets remained as responsive as wild-type islets to glucose (Supple-
mental Figure 2, A–C). In wild-type islets, insulin secretion above 
basal (1 mM) was >15-fold higher at 20 mM glucose than at 6 mM. 
Figure 8. GLP-1 stimulates electrical activity by 
activation of a Na+-dependent and KATP channel–
independent mechanism. (A and B) Membrane 
potential recording from (A) mouse (n = 6 cells from 
2 mice) and (B) human (n = 4 cells from 3 donors) 
β cells. Tolbutamide and GLP-1 were added as indi-
cated above traces. Electrical activity in the pres-
ence of glucose and tolbutamide was suppressed by 
injection of hyperpolarizing current (–1.5 pA in A and 
–9 pA in B as indicated) in the different experi-
ments. For clarity, the recordings have been color 
coded (gray, 6 mM glucose; black, after addition of 
tolbutamide; blue, after injection of hyperpolarizing 
current; red, after application of GLP-1). (C) GLP-1 
remains capable of depolarizing mouse β cells in the 
presence of the L-type Ca2+ channel blocker isradip-
ine but does not evoke action potential firing (n = 6 
from 3 mice). The depolarizing action of GLP-1 was 
reversibly suppressed by lowering [Na+]o to 28 mM 
(“20% Na”) (n = 3 from 2 mice).
The Journal of Clinical Investigation R e s e a R c h  a R t i c l e
4 7 2 2 jci.org   Volume 125   Number 12   December 2015
Discussion
We have revisited the mechanisms by which 
GLP-1 stimulates insulin secretion in mouse 
and human β cells. Most previous in vitro 
studies have been conducted in cell lines or 
using rodent islets, and it is not immediately 
evident to what extent these findings can be 
extended to humans. Another problem is that 
most in vitro studies have employed very high 
concentrations of GLP-1 (1,000- to 10000-
fold higher than the peripheral plasma con-
centration). Here, we have characterized 
the effects of physiological concentrations 
of GLP-1 (1–10 pM) on insulin secretion and 
electrical activity. We show that such low con-
centrations are as effective (if not more effec-
tive) as the higher concentrations previously 
employed. We dissect the signal transduction 
pathways involved and provide evidence for 
the involvement of a PLC/PKC-dependent 
mechanism, culminating in the activation of 
a Na+-permeable conductance. Here, we dis-
cuss key aspects of this work. We first consider 
the mechanism by which physiological con-
centrations exert the stimulatory effect on the 
β cell. We then turn to the functional implications of our findings 
and the impact they have on the mechanism of action of GLP-1 in 
vivo. Figure 11 summarizes schematically the effects of low con-
centrations of GLP-1 on β cell signal transduction pathways that 
culminate in stimulation of insulin secretion.
Picomolar concentrations of GLP-1 stimulate insulin secretion 
by PKC-dependent mechanisms. We found that a large compo-
nent of the stimulatory effect of GLP-1 on glucose-stimulated 
insulin secretion was sensitive to inhibitors of PKA (such as 
Rp-8-Br-cAMPS and myr-PKI). Unexpectedly, 40% of the stim-
ulatory effect on insulin secretion persisted in the presence of 
myr-PKI and GLP-1 remained capable of stimulating β cell elec-
trical activity in the presence of PKA inhibitors.
We believe that the PKA-resistant component depends on 
PKC activity. This is suggested by the observation that the PKC 
inhibitors BIM and calphostin C abolished the stimulatory effect 
ingly, application of GLP-1 (1 pM) in the presence of diazoxide still 
increased [Ca2+]i, but the effect was smaller and did not exhibit any 
oscillations but only an increase to a new plateau level (Figure 10E). 
The experiments were concluded by membrane depolarization pro-
duced by increasing the extracellular K+ concentration ([K+]o) to 50 
mM. This invariably elicited a large increase in [Ca2+]i, both in the 
absence and presence of diazoxide. When GLP-1 was applied in the 
presence of diazoxide and to cells pretreated with thapsigargin (1 
μM), no GLP-1–induced increase in [Ca2+]i was observed (Figure 10F).
Finally, we ascertained that GLP-1 did not evoke electrical 
activity in the presence of the KATP channel activator diazoxide. 
When applied to β cells exposed to 6 mM glucose, diazoxide (200 
μM) hyperpolarized the membrane potential to –80 ± 1 mV. Appli-
cation of GLP-1 induced a reversible depolarization of 10 ± 4 mV 
(P < 0.05, paired Student’s t test) but did not evoke action potential 
firing (Figure 10G).
Figure 9. GLP-1 acts by a TRPM4- and TRPM5-de-
pendent mechanism. (A–C) Effects of 10 pM GLP-1 
on insulin secretion in islets from (A) wild-type, (B) 
Trpm4–/–, and (C) Trpm5–/– mice exposed to 6 mM 
glucose. *P < 0.05 vs. 6 mM glucose (n = 6 islets 
from 7–9 mice; 1-way ANOVA with Dunnett’s post-
hoc test). (D–F) Effects of GLP-1 (1 pM to 10 nM) on 
electrical activity in (D) wild-type (n = 5 cells from 
2 mice), (E) Trpm4–/– (n = 9 cells from 5 mice), and 
(F) Trpm5–/– (n = 7 cells from 5 mice) β cells isolated 
from C57BL6/N mice. (G) Histogram summarizing 
action potential frequency in β cells exposed to 6 
mM glucose in the absence or presence of GLP-1 glu-
cose in wild-type, Trpm4–/–, and Trpm5–/– β cells as in 
D–F. *P < 0.05 vs. 6 mM glucose (Student’s t test); 
†P < 0.05 vs. 6 mM glucose plus GLP-1 (wild-type; 
1-way ANOVA with Dunnett’s post-hoc test).
The Journal of Clinical Investigation   R e s e a R c h  a R t i c l e
4 7 2 3jci.org   Volume 125   Number 12   December 2015
cal inhibition of PLC abolished the stimulation of 
β cell electrical activity induced by GLP-1. Third, 
application of GLP-1 at picomolar concentrations 
led to an increased intracellular concentration of 
DAG (Figure 4, C and D).
It may seem surprising that the PKC inhibitors 
abolished the stimulatory effect on insulin secre-
tion, given that the PKA-resistant component of 
GLP-1–induced secretion only amounted to 40% 
of the total stimulatory effect. This we attribute to 
a hierarchy of the PLC/PKC- and PKA-dependent 
effects. Whereas PKC is required for the initiation 
of electrical activity and stimulation of Ca2+ influx, 
the PKA-dependent mechanism principally 
potentiates the downstream effects by enhanced 
Ca2+-dependent exocytosis. Thus, the PKA- 
dependent effects will not operate in the absence 
of electrical activity (which is PKC dependent).
In addition to the PKA- and PKC-dependent 
effects we discuss above, GLP-1 has also been pos-
tulated to activate the low-affinity cAMP-sensing 
protein Epac-2. However, the finding that GLP-1, 
when applied at a concentration of 1 pM, has 
almost no effect on intracellular cAMP levels, 
makes it unlikely that the low-affinity cAMP sen-
sor Epac-2 contributes much to the stimulatory 
effect of picomolar concentrations of GLP-1.
The observation that GLP-1 did not increase intracellular 
cAMP (Figure 3, C and D) may seem in conflict with the finding 
that 60% of its stimulatory action on insulin secretion was inhib-
ited by myr-PKI (Figure 3A). It could be argued that GLP-1 may 
produce an increase in cAMP too small to be detected by the assay 
we used here, but this explanation seems less likely, given that our 
measurements of PKA activity failed to detect any increase in its 
activity in response to GLP-1. Importantly, pretreatment of the 
cells with myr-PKI reduced basal PKA activity (Figure 3, E and F). 
Thus, it appears that PKA is tonically active in the β cell and that 
such activity is required for the full secretory response. Indeed, 
of GLP-1 on insulin secretion, while not affecting that evoked by 
glucose alone. Further evidence for the involvement of PKC in 
the stimulatory effect of GLP-1 comes from the observations that 
its effect on β cell electrical activity can be mimicked by the PKC 
activator PMA and the ability of GLP-1 to produce PKC-depen-
dent phosphorylation of PKD1, previously identified as a regulator 
of insulin secretion (39). It seems possible that activation of PKC 
is downstream of G
αq-dependent activation of PLC. This is sug-
gested by three pieces of evidence. First, GLP-1 binding to GLP-1R 
led to the activation of G
αq in a yeast recombinant system express-
ing the mammalian G protein (Figure 5). Second, pharmacologi-
Figure 10. GLP-1 mobilizes intracellular Ca2+. (A and B) 
Effects of GLP-1 (10 pM) on insulin secretion in islets from 
(A) wild-type and (B) Tpc1 Tpc2 DKO mice exposed to 6 
mM glucose (n = 7–8 islets from 6–7 mice). *P < 0.05 vs. 6 
mM glucose (1-way ANOVA with Dunnett’s post-hoc test). 
(C) Effects of 10 pM GLP-1 on electrical activity in Tpc1 
Tpc2 DKO β cells. Note that GLP-1 stimulates electrical 
activity in Tpc1 Tpc2 DKO β cells (n = 4). (D–F) Change in 
fluo-3 fluorescence (ΔF/F0) measured in single cells in 
small islet cell clusters from NMRI mice. Diazoxide (200 
μM), GLP-1 (1 pM), [K+]o (50 mM), and thapsigargin (1 μM) 
were applied as indicated by horizontal lines. Represen-
tative traces of 7 to 12 cells from 3 to 7 experiments. (G) 
Failure of GLP-1 to evoke electrical activity in the presence 
of diazoxide (200 μM). Glucose was present at a concen-
tration of 6 mM throughout. Note spontaneous action 
potential firing at 6 mM glucose, suppression of action 
potential firing, and membrane repolarization evoked by 
application of diazoxide and small and reversible depolar-
ization produced by GLP-1 (n = 6 from 4 mice).
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presence of a maximally inhibitory concentration of tolbutamide. 
Collectively, these observations suggest that closure of KATP chan-
nels is not the sole mechanism by which GLP-1 stimulates β cell 
electrical activity.
In both mouse and human β cells, the ability of GLP-1 to produce 
membrane depolarization and initiate action potential firing was 
dependent on extracellular Na+. Thus, we confirm earlier reports 
that the action of GLP-1 involves a Na+-dependent mechanism (40, 
41). However, the molecular identity of this Na+-permeable con-
ductance was not conclusively established previously, and it is also 
unclear whether similar mechanisms operate in mouse and human 
β cells. We can exclude involvement of voltage-gated Na+ chan-
nels, because tetrodotoxin did not interfere with the stimulatory 
action of GLP-1 (data not shown). In voltage-clamp measurements, 
GLP-1 activated a small voltage-independent Na+-dependent 
inward current with an amplitude of only approximately 10 pA. 
However, because the input resistance of the β cell is very high 
(>1 GΩ) in the presence of insulin-releasing glucose concentra-
tions, even currents as small as this can exert a marked depolariz-
ing effect on the membrane potential (>10 mV) and trigger action 
potential firing. It is implicit from the small current activated by 
GLP-1 that it will not be able to initiate electrical activity and insulin 
secretion unless the KATP channels are almost fully inhibited. This 
explains why the stimulatory effect of GLP-1 is glucose dependent, 
with no or little stimulatory action at low glucose concentrations 
(Figure 1, B and C), and why GLP-1 loses its stimulatory effect on 
β cell electrical activity in the presence of diazoxide. It is likely that 
our failure to detect much suppression of the resting K+ conduc-
tance (principally reflecting KATP channel activity) is because the 
increase in membrane conductance resulting from the activation 
of a background Na+-dependent current obscures the reduction 
due to closure of the KATP channels.
Our membrane potential and insulin secretion measurements 
in Trpm4–/– and Trpm5–/– β cells and islets suggest that both TRPM4 
and TRPM5 channels are crucial to the stimulatory effect of phys-
iological concentrations of GLP-1. We attributed the stimulatory 
effect of GLP-1 on β cell electrical activity, which remained after 
lowering [Na+]o, to membrane depolarization, resulting from KATP 
channel closure. A role of TRPM5 channels in the response to GLP-
1 is also consistent with the reported deterioration of glucose toler-
ance following oral glucose administration in Trpm5 KO mice (23).
TRPM4 and TRPM5 channels are Ca2+ activated (42). It 
is therefore of interest that application of GLP-1 produced an 
increase in [Ca2+]i in hyperpolarized cells, suggesting it reflects 
mobilization from intracellular Ca2+ stores, that was sensitive 
to the SERCA inhibitor thapsigargin. It is also possible that the 
TRPM4 and TRPM5 channels are regulated by PKC in a Ca2+-inde-
pendent way at the ambient submembrane [Ca2+]i. In this context, 
it is of interest that the PKC activator PMA mimics the effect of 
GLP-1 on electrical activity, and there is documented evidence for 
modulation of TRPM4 and TRPM5 by PKC (43, 44).
Coda. Information on the concentration dependence of the 
insulinotropic effect of GLP-1(7-36) has important physiological 
implications. The concentrations of GLP-1 customarily used in vitro 
(1–100 nM) (12–15) are several orders of magnitude higher than the 
physiological total plasma concentrations and even the portal con-
centration (>20 pM, ref. 45). In fact, most of the GLP-1 secreted 
not only the effect of GLP-1 was reduced by pretreatment with 
myr-PKI; there was also a tendency toward reduced insulin secre-
tion to 6 mM glucose.
GLP-1 stimulates electrical activity by a Na+-dependent mech-
anism. We found that GLP-1 increases the amplitude of the volt-
age-gated Ca2+ current. Pancreatic β cells are equipped with sev-
eral types of voltage-gated Ca2+ channel, but our measurements 
in both mouse and human β cells suggest that GLP-1 selectively 
increases the L-type Ca2+ current, as no stimulation was detected 
in the presence of isradipine, a blocker of L-type Ca2+ channels. It 
is important to note, however, that the effect of GLP-1 on the Ca2+ 
current is fairly small and that GLP-1 had no effect on the gating of 
the current. Thus, we argue that the contribution of the increased 
Ca2+ current to the stimulatory effect of GLP-1 on electrical activ-
ity and insulin secretion is marginal.
Our Ca2+ imaging experiments as well as membrane poten-
tial recordings suggest that an important component of the stim-
ulatory action of GLP-1 is mediated by initiation of electrical 
activity (Figure 1D). Part of this effect may result from enhanced 
glucose-induced closure of the KATP channels (as was previously 
reported, refs. 24, 26). Importantly, we observed no net reduction 
of the resting membrane conductance in response to GLP-1 and 
GLP-1 remained capable of stimulating electrical activity in the 
Figure 11. Schematic summarizing the effects of GLP-1 on signal transduc-
tion pathways relevant to the stimulation of insulin secretion. In addition to 
activating G
αs, GLP-1 also leads to activation of Gαq, leading to the activation 
of PLC and production of DAG, with resultant activation of PKC and elevation 
of [Ca2+]i by IP3-induced Ca
2+ mobilization from thapsigargin-sensitive Ca2+ 
stores, which (together with the activation of PKC) results in activation of 
TRPM4 and TRPM5 channels, membrane depolarization, and initiation of 
action potential firing. GLP-1 also stimulates Ca2+ entry via L-type Ca2+ chan-
nels, but this effect is relatively small and is not sufficient to explain the initi-
ation of electrical activity. Additionally, GLP-1 closes KATP channels, accounting 
for the weak depolarization that persists at low extracellular Na+ and in some 
Trpm4–/– and Trpm5–/– β cells. Low concentrations of GLP also enhanced 
depolarization-evoked exocytosis, but this effect requires electrical activity/
Ca2+ entry to operate. This also explains why PKC inhibition leads to complete 
loss of insulin secretion stimulated by GLP-1. This is because, unless electrical 
activity is initiated, these distal effects will not operate. In the schematic, 
pharmacological activators and inhibitors are highlighted in red and blue, 
respectively. AC, adenylyl cyclase; VDCC, voltage-dependent Ca2+ channels.
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Electrophysiological recordings. All recordings were performed 
using an EPC-9 patch-clamp amplifier (HEKA Electronics) using the 
perforated patch whole-cell technique. Amphotericin B (0.24 mg/ml) 
was used to establish electrical contact with the cell interior as previ-
ously described (58). The extracellular solution for recordings of mem-
brane potential contained 140 mM NaCl, 3.6 mM KCl, 1.5 mM CaCl2, 
0.5 mM MgSO4, 0.5 mM NaH2PO4, 5 mM NaHCO3, 10 mM HEPES, 
and 6 mM glucose (pH 7.4, with NaOH). The pipette solution consisted 
of 128 mM K-gluconate, 10 mM NaCl, 10 mM KCl, 1 mM MgCl2, and 5 
mM HEPES (pH 7.35, with KOH). The extracellular solution for record-
ings of Ca2+ currents and capacitance contained 118 mM NaCl, 5.6 mM 
KCl, 2.6 mM CaCl2, 1.2 mM MgCl2, 5 mM HEPES, 20 mM TEA-Cl, 
and 6 mM glucose (pH 7.4, with NaOH). The pipette solution consisted 
of 76 mM Cs2SO4, 10 mM NaCl, 10 mM KCl, 1 mM MgCl2, and 5 mM 
HEPES (pH 7.35, with CsOH). When extracellular Na+ was reduced to 
20% of the normal concentration, it was substituted equimolarly by 
the nonpermeant cation N-methyl-d-glucamine+.
For the measurement of exocytosis and Ca2+ currents, the cells 
were voltage clamped at –70 mV, and voltage-dependent calcium 
channels were activated by 20-ms depolarizations to 0 mV applied at 
1-minute intervals for measuring the effects of GLP-1 on the magni-
tude of the Ca2+ current.
Exocytosis was measured as increases in cell capacitance evoked 
by 500-ms depolarizations from –70 mV to 0 mV before and 10 min-
utes after applying GLP-1 using the Sine+DC technique (59).
Effects of GLP-1 on the whole-cell KATP channel conductance were 
measured in the perforated patch mode by interrupting the membrane 
potential recordings (in the current-clamp mode) and switching the 
amplifier into the voltage-clamp mode. The whole-cell KATP conduc-
tance was then measured by application of ±10 mV voltage excursion 
from a holding potential of –70 mV. All electrophysiological measure-
ments were made at +32°C. The identity of the β cells was confirmed 
by immunohistochemistry as described previously (60, 61).
[Ca2+]i measurements. Confocal [Ca2+]i imaging in intact islets 
was conducted essentially as described previously (62). [Ca2+]i imag-
ing was also performed on isolated cells or small clusters following 
dissociation of the islets. In these experiments, cells were plated in 
glass-bottom dishes and maintained in tissue culture overnight in 
RPMI 1640 medium containing 10 mM d-glucose. Prior to the exper-
iments, the cells were washed twice in imaging buffer (63) contain-
ing 6 mM d-glucose and then loaded with 2 μM fluo-3AM in the same 
buffer for 45 minutes at 30°C. After removal of the loading buffer, the 
cells were incubated for another 45 minutes in the absence of the indi-
cator to allow complete de-esterification. In some experiments, 1 μM 
thapsigargin was added during the de-esterification step after 25 min-
utes. The cells were superfused at a rate of approximately 1 ml/min, 
and images were acquired on a Zeiss Axio Observer with ×40/1.2W 
C-Apo Corr lens and illuminated by a Zeiss Colibri.2 system at 488 nm 
with 15-ms exposure and 2 frames per second. Data are depicted as 
change in background corrected fluorescence relative to fluorescence 
at the beginning of the recordings.
cAMP measurements. The effect of GLP-1 on cAMP levels ([cAMP]i) 
in pancreatic islet cells was studied using a recombinant FRET sen-
sor, Epac2-camps (27). Epac2-camps was delivered via an adeno-
viral infection (104 units per cell). The imaging experiments were 
performed 36 to 48 hours after infection using a Zeiss Axioskop 2FS 
microscope equipped with a ×40/1.3 objective, Lambda DG-4 exciter 
by the intestinal L cells is rapidly degraded by DPP-4 and never 
reaches the pancreatic islets (46). If GLP-1 is only active at nanomo-
lar concentrations (as suggested by in vitro assays of cAMP produc-
tion; refs. 47, 48), then it is highly unlikely that circulating GLP-1 will 
stimulate insulin secretion. These considerations prompted the idea 
that the hormone instead acts by activation of vago-vagal reflexes 
(49). However, our findings that GLP-1 at concentrations as low as 1 
pM evokes electrical activity in β cells and results in a strong stimu-
lation of insulin secretion in both mouse and human cells/islets (in 
agreement with previous findings in mouse insulinoma cells; refs. 
50, 51) argue that circulating levels of GLP-1(7-36) are adequate to 
account for the incretin effect. The concept that circulating levels 
mediate the effects of GLP-1 in vivo is also easily reconciled with 
the observation that the incretin effect remains intact in patients 
that have received a whole-pancreas transplant (52), i.e., when the 
normal innervation has been surgically severed.
Methods
Chemicals. GLP-1(7-36) amide and the GLP-1R antagonist exendin 
(9-39) were purchased from Bachem. The L-type calcium channel 
blocker isradipine was purchased from Alomone Labs. The mem-
brane-permeable PKA inhibitors Rp-8-Br-cAMPS and myr-PKI were 
obtained from Biolog Life Science Institute and TOCRIS, respec-
tively. The PKC inhibitors BIM and calphostin C were from Merck. 
Thapsigargin was purchased from TOCRIS. Tolbutamide, diazoxide, 
acetyl choline, PMA, U-73122 hydrate, and other compounds were 
obtained from Sigma-Aldrich.
Animals, mouse islet isolation, and cell culture. Most experiments 
were performed using islets and/or β cells isolated from female NMRI 
mice (Charles River), fed a normal diet ad libitum.
Trpm4–/– and Trpm5–/– mice were generated as previously described 
(35, 53). Both mouse lines were backcrossed for 9 generations on the 
C57BL6/N background.
DKO mice for both Tpc1 and Tpc2 genes were derived from 
dihybrid crosses between Tpc1T159 (54) and Tpc2YHD437 (55) homozy-
gote mutant animals. Lack of Tpc1 and Tpc2 expression was con-
firmed by RT-PCR. Age- and sex-matched C57BL6/N wild-type 
animals were used as controls.
Mice were kept in a conventional vivarium with a 12-hour-dark
/12-hour-light cycle and ad libitum access to food and water and were 
killed by cervical dislocation.
Pancreatic islets were isolated by collagenase as previously reported 
(25). For preparation of single β cells (electrophysiology), freshly iso-
lated islets were incubated in enzyme-free Hank’s medium (Invitro-
gen) and dissociated into cells/cell clusters by gentle trituration using 
a 1,000-μl pipette. Dispersed cells were plated on plastic 35-mm tissue 
culture dishes (Sarstedt Inc.) and maintained in RPMI 1640 containing 
10 mM glucose (mouse) or 7.5 mM glucose (human) supplemented with 
10% calf serum, 100 U/ml penicillin, and 100 μg/ml streptomycin (Life 
Technologies Corporation). The cells were maintained in tissue culture 
for up to 36 hours before the electrophysiological experiments.
Human islets. Pancreatic islets were isolated in the Oxford Diabe-
tes Research & Wellness Foundation Human Islet Isolation Facility 
according to published protocols (56, 57). Single β cells were prepared 
for electrophysiology essentially as described above for mouse cells.
Insulin measurements. Static and dynamic measurements of insu-
lin release were performed as reported previously (25).
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detection reagent (Clarity Western ECL substrate, Bio-Rad) and exposure 
to X-ray film (Amersham Hyperfilm ECL, GE Healthcare). Each phos-
pho-PKD blot was stripped and reprobed for total PKD1 to determine acti-
vation (phospho-PKD/total PKD intensity ratios). Data were expressed as 
mean fold change relative to no stimulation control in each experiment.
Yeast-based assay of GLP-1R activation of G proteins. Yeast nitro-
gen base and yeast extract were purchased from Difco. Fluores-
cein-di-β-d-glucopyranoside (FDGlu) was purchased from Invit-
rogen. General yeast procedures were performed as described 
previously (23, 56). We have previously demonstrated the expression 
of human GLP-1R in dual-reporter chimeric Gαq, and Gαs (MMY14 
and MMY24) containing Saccharomyces cerevisiae strains (33). Recep-
tor signaling was measured using the yeast growth assay. Cells were 
initially grown in SD-URA to establish a starter culture prior to over-
night growth in SD-URA-HIS media at 30°C to remove basal activ-
ity. Yeast cells were then assayed using FDGlu-supplemented media 
in the presence of different concentrations of GLP-1 ligand (0.01 
nM–10 μM). Fluorescence was measured on a TECAN Infinite M200 
microplate reader (TECAN Ultra Evolution).
Statistics. Statistical analyses were performed using IBM SPSS 
statistics software. Unless otherwise indicated, data are presented as 
mean ± SEM. Statistical significance was evaluated using the 2-tailed 
Student’s t test (single comparisons), ANOVA (multiple comparisons), 
or Friedman’s test with Dunn-Bonferroni post-hoc (multiple compari-
sons on paired nonparametric data). Dunnett’s test was used for post-
hoc analysis with ANOVA where data were compared with a single 
control or with multiple controls. A P value of less than 0.05 was con-
sidered significant. All experiments on wild-type cells were performed 
on cells/islets pooled from multiple animals.
The concentration-response relationships (Figure 4) were ana-
lyzed using Prism 6.0e (Graphpad Software) using the 3-parameter 
logistic equation to obtain EC50 and the maximal effect (Emax) values.
To derive the Ca2+ channel activation properties, the currents (I) elic-
ited by membrane depolarization to voltage V were divided by the driv-
ing force (V – ECa, where ECa represents the reversal potential for the Ca2+ 
current determined experimentally for each experiment). The maximal 
current (Imax) and ECa were obtained by fitting each current-voltage (I-V). 
The individual activation relation was fitted to the function
  (Equation 1)
where Vh is the membrane potential at which the activation is half-
maximal and k is the slope factor.
The dose-response relationship between GLP-1 and cytosolic 
cAMP (measured as R) was fitted with a Hill equation
  (Equation 2)
(Sutter Instruments), and Orca-R2 cooled CCD camera (Hamam-
atsu). The CFP fluorescence was excited at 436 nm; the emitted light 
was collected at 485 nm and 535 nm using a Dual-View Beamsplitter 
(Photometrics). The images were acquired using open-source Micro- 
Manager software (developed at Ron Vale’s lab, UCSF, San Francisco, 
California, USA), and fluorescence (F) was normalized to the initial 
fluorescence (F0), after which the CFP/YFP ratio (R) was calculated 
(using ImageJ) by dividing the intensity of fluorescence emitted at 485 
nm (CFP) with that emitted at 535 nm (YFP). Data analysis and repre-
sentation were performed with Igor Pro (Wavemetrics).
PKA activity measurements. Real-time changes in PKA activity were 
reported in pancreatic islet cells using recombinant FRET probe AKAR3 
(28). Islets isolated from NMRI mice were dispersed into single cells and 
plated on glass coverslips. AKAR3 was delivered via an adenoviral infec-
tion (103 units per cell). Imaging experiments were performed 36 hours 
after infection using a Zeiss Axioskop FS2 microscope equipped with a 
×40/1.3 objective (Carl Zeiss). The fluorescence was excited at 436 nm; 
the emitted light was collected at 485 (CFP) and 515 (YFP) nm. The cells 
were kept at 33°C to 35°C and superfused continuously throughout the 
experiment. The images were acquired using Micro-Manager software 
and fluorescence (F) normalized to the initial fluorescence (F0) using 
ImageJ. Data analysis and representation were performed with Igor 
Pro (Wavemetrics). AKAR3 was a gift from Jin Zhang, Department of 
Pharmacology and Molecular Sciences, The Johns Hopkins University 
School of Medicine, Baltimore, Maryland, USA.
DAG measurements. The effect of GLP-1 on [DAG]i in pancreatic 
islet cells was studied using a recombinant circularly permutated probe, 
Upward DAG (Montana Molecular). Islets isolated from NMRI mice 
were dispersed into a single-cell suspension as described above and 
plated on glass coverslips. Upward DAG was delivered via a BacMam 
infection (103 units per cell), according to the manufacturer’s guidelines. 
Imaging experiments were performed 48 hours after infection using 
a Zeiss AxioZoom.V16 zoom microscope equipped with a ×2.3/0.57 
objective (Carl Zeiss). The fluorescence was excited at 480 nm, and the 
emitted light was collected at 515 nm. The cells were kept at 33°C to 35°C 
and superfused continuously throughout the experiment. The images 
were acquired using Zen Blue software (Carl Zeiss) and normalized to 
the initial fluorescence and reported as F/F0 using ImageJ. Data analysis 
and representation was performed with Igor Pro (Wavemetrics).
Determination of PKC-dependent activation of PKD1. Freshly iso-
lated mouse islets were handpicked and maintained in RPMI supple-
mented with 6 mM glucose, 10 mM HEPES, and 0.1% BSA for 5 hours 
prior to stimulation. Islets (150 per condition) were subsequently pre-
incubated in RPMI with or without BIM for 60 minutes and stimulated 
for 10 minutes with the compounds indicated in the figure legends.
After incubation, the supernatants were discarded; islets were 
washed in ice-cold PBS once and lysed in RIPA buffer containing 20 
mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% 
NP-40, 1% sodium deoxycholate, 2.5 mM β-glycerophosphate, and 1 
mM Na3VO4; and supplemented with protease and phosphatase inhib-
itors (Life Sciences/Roche).
The lysates were subjected to SDS-PAGE, transferred to PVDF mem-
brane (Bio-Rad), and probed with primary antibodies to phospho-PKD1 
(Ser744/748 2054, Cell Signaling Technology) and total PKD1 (2052, 
Cell Signaling Technology), calnexin (208880, Calbiochem), and β- 
actin (ab49900, AbCam). HRP-conjugated secondary anti-mouse and 
anti-rabbit antibodies were from Dako. Blots were visualized using ECL 
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and MZ contributed to the measurements of PKA activity. AG, MK, 
GL, RV, and KK contributed to the discussion. MS and PR planned the 
experiments and wrote the paper.
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